2 weeks Ago By Defense World Staff
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL – Get Free Report ) shares shot up 4.8% during mid-day trading on Thursday after Piper Sandler raised their price target on the stock from $15.
00 to $23.00. Piper Sandler currently has a neutral rating on the stock.
Rigel Pharmaceuticals traded as high as $28.90 and last traded at $28.73.
100,289 shares were traded during mid-day trading, a decline of 37% from the average session volume of 160,428 shares. The stock had previously closed at $27.41.
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research note on Friday, October 25th.
Cantor Fitzgerald reiterated a “neutral” rating and set a $15.00 price target on shares of Rigel Pharmaceuticals in a research note on Friday, September 20th. Citigroup raised their price objective on shares of Rigel Pharmaceuticals from $40.
00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, StockNews.
com upgraded shares of Rigel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 18th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Rigel Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $31.
30. Check Out Our Latest Stock Report on Rigel Pharmaceuticals Hedge Funds Weigh In On Rigel Pharmaceuticals Rigel Pharmaceuticals Price Performance The stock has a 50 day moving average of $15.85 and a two-hundred day moving average of $12.
24. The stock has a market capitalization of $483.71 million, a PE ratio of 196.
14 and a beta of 0.96. About Rigel Pharmaceuticals ( Get Free Report ) Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. See Also Five stocks we like better than Rigel Pharmaceuticals Where to Find Earnings Call Transcripts 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick Are Penny Stocks a Good Fit for Your Portfolio? Mouse Rising: The Iger Investment Pays Off for Disney Investors What is a Special Dividend? Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
